We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




First Mobile Diagnostic System Performs Instant Lab Quality Blood Analysis Anywhere

By LabMedica International staff writers
Posted on 25 Aug 2023

Presently, the complete blood count (CBC) is one of the most frequently recommended diagnostic tests to evaluate an individual's overall health by measuring factors like oxygen-transporting red blood cells, infection-combating white blood cells, and blood-coagulating platelets. More...

However, there are issues with CBC testing such as patient expenses, accessibility, and time consumption. Patients require a referral, followed by scheduling a nurse appointment for blood collection. This is followed by waiting in the clinic, and sometimes waiting for hours or days after the blood draw to obtain the results. Moreover, a substantial portion of the global population lacks access to proper diagnostics due to distance from clinics or financial constraints. Now, a groundbreaking diagnostic system is making waves in the point of care (POC) setting, offering the first mobile technology for instant blood analysis beyond the confines of a lab. This innovation has the potential to bring lab tests within reach of millions worldwide.

The REVDX from EFA Technologies (Caesarea, Israel) is a portable lab-quality device that incorporates advanced multi-channel technology. This handheld device can be used anywhere, eliminating the need for time-consuming preparations or specialized knowledge. It is mobile, portable, and handheld, capable of functioning without electricity or internet connectivity, while also being cost-effective. At present, the device can conduct a blood count, with plans for additional tests in the future. A simple finger prick is all that's required, eliminating the need to visit a lab and delivering results in just minutes. The device aims to empower doctors and medical teams in diverse scenarios to make informed treatment decisions promptly, bypassing the wait time for blood tests and their subsequent results. The REVDX is user-friendly, operating via a finger prick and independent of elaborate lab conditions or specific preparations.

In patients with fever, the most critical test to conduct is a CBC. These results can assist in administering antibiotics for suspected bacterial infections, avoiding unwarranted antibiotic use in viral infections, and identifying parasitic infections like malaria. Presently, most labs provide CBC results within 24 to 72 hours, with a significant time lapse during test transportation. The absence of real-time blood count data contributes to antibiotic overuse, which exacerbates antimicrobial resistance (AMR). REVDX has the capability to conduct automated microscopy tests, encompassing full blood sampling and immediate full blood count diagnosis. Physicians can utilize REVDX to make real-time, informed judgments about the likelihood of a bacterial infection, curtailing unnecessary antibiotic use. This positions REVDX as an indispensable device for every point of need across the world.

Related Links:
EFA Technologies 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Platelet Function Analyzer
PL-12
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.